Femoral Fracture Clinical Trial
— PEGASUSOfficial title:
Post Market Clinical Evaluation of Gamma 4: Prospective, Multicenter, Follow-up Study (PEGASUS)
NCT number | NCT05523635 |
Other study ID # | TA-01-2022 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 6, 2023 |
Est. completion date | June 30, 2025 |
This is a prospective, multi-center, non-randomized, post-market clinical investigation of the Gamma 4 System. Neither subjects nor investigators are blinded to treatment. It is anticipated that a total of 100 subjects will be enrolled at five sites. Total duration of enrollment, 12 month follow-up and analysis is expected to take approximately 30 months. The clinical investigation has been designed to follow the surgeon's standard of care for subjects treated with a cephalomedullary nail for femoral fractures or and deformities, in addition to a 12 month follow-up visit. The primary endpoint of this clinical investigation is demonstration of bone consolidation by 12 months.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | June 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject is a male or non-pregnant female age 18 years or older at the time of surgery; - Subject is willing and able to give written informed consent and comply with the requirements of this Clinical Investigation Plan; and - Subject has or is intended to be treated with the Gamma 4 System in accordance with its legally approved Indication for Use (IFU). Indication For Use in the United States and Canada: The Gamma4 System is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone). Exclusion Criteria: - Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results - Subject with exclusion criteria required by local law - Subject who is, or will be, inaccessible for follow-up - Per the Investigator, the subject is in poor general health or undergoing any concurrent disease that would place the subject in excessive risk to surgery (i.e., significant circulatory problems, cardiac disease). - Any active or suspected latent infection or marked local inflammation in or about the affected area - Compromised vascularity that would inhibit adequate blood supply to the fracture or the operative site - Bone stock compromised by disease, infection or prior implantation that cannot provide adequate support and/or fixation of the devices - Material sensitivity, documented or suspected - Patients having inadequate tissue coverage over the operative site - Implant utilization that would interfere with anatomical structures or physiological performance - Any mental or neuromuscular disorder which would create an unacceptable risk of fixation failure or complications in postoperative care - Other medical or surgical conditions which would preclude the potential benefit of surgery. |
Country | Name | City | State |
---|---|---|---|
United States | MetroHealth | Cleveland | Ohio |
United States | Inova Health Care Services | Falls Church | Virginia |
United States | SSM Health - Madison | Madison | Wisconsin |
United States | William Beaumont Hospital | Royal Oak | Michigan |
United States | UT Health | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Stryker Trauma GmbH |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bone Consolidation via Clinical Assessment | Clinical consolidation is defined as no pain or tenderness when weight bearing | by 12 months | |
Primary | Bone Consolidation via Radiographic Assessment | Radiographic bony consolidation is defined as bridging of the fracture at three of four cortices. | by 12 months | |
Secondary | Safety will be measured by capturing the incidence rate of device-related adverse events | Incidence of device related intra-operative and post-operative Adverse Events/incidents by 12 months. | 12 months | |
Secondary | SF-36v2® Physical Component Score and Mental Component Score (PCS & MCS) | The SF-36 PCS is a self-report measure of health status. SF-36 Physical Component Summary scores range from 0 to 100; higher SF-36 score results are linked to better subject results.
Efficacy/performance at 12 months will be measured by the SF-36 Physical Component Score (PCS) compared to the pooled literature controls. |
12 months | |
Secondary | Modified Harris Hip Score | The modified Harris Hip Score is a hip-specific questionnaire which evaluates hip pain and function. It is a commonly used and validated tool.
Efficacy/performance at 12 months will be measured by the modified Harris Hip Score compared to the pooled literature controls. |
12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05515718 -
Effect of the Early Ultrasound-guided Femoral Nerve Block Performed by Emergency Physicians on Pre-operative Opioids Usage in Patients With Proximal Femoral Fractures
|
N/A | |
Recruiting |
NCT04494672 -
A Study to Verify if the Surgery for the Proximal Femur Fracture Can be Improved With the Help of a Navigation System
|
N/A | |
Unknown status |
NCT01680120 -
Dose Finding Study for Continuous Spinal Anaesthesia
|
Phase 4 | |
Recruiting |
NCT04015128 -
A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail GT
|
||
Recruiting |
NCT04015154 -
A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail PF
|
||
Recruiting |
NCT05410587 -
Fracture Monitor - Femur
|
N/A | |
Recruiting |
NCT05276674 -
ZNN Bactiguard Retrograde Femoral Nails PMCF Study
|
||
Completed |
NCT02983344 -
Analgesia For Positioning Patient With Femur Fracture For Spinal Anaesthesia
|
N/A | |
Terminated |
NCT00764959 -
Retrospective Study of the Linearâ„¢ Hip
|
Phase 4 | |
Completed |
NCT02069327 -
The Role of Fat Emboli in the Trauma Inflammatory Response
|
||
Completed |
NCT03856502 -
Influence of Intrathecal Dexamethasone Administration for Proximal Femoral Fractures
|
N/A | |
Recruiting |
NCT05559736 -
Artemis Proximal Femoral Nail for Internal Fixation of Intertrochanteric Femur Fractures
|
N/A | |
Completed |
NCT03810092 -
Analysis of the Relationship Between Early Postoperative Anemia and the Evolution of Autonomy at 6 Months in Patients 75 Years of Age and Older Operated on Following a Fracture of the Upper End of the Femur
|
||
Recruiting |
NCT05087667 -
Study of the Effectiveness of a Polymer Cerclage System Compared to Cerclages Used in Standard Care (CERCPMCF) )
|
N/A | |
Recruiting |
NCT05274022 -
Rehabilitation Strategies to Improve Outcomes For Patients With a Lower Extremity Fracture
|
N/A | |
Terminated |
NCT01300520 -
The Development of a Surgical Localizing Aid Medical Device
|
N/A | |
Terminated |
NCT01141894 -
Goal Directed Haemodynamic Treatment for Patients With Proximal Femoral Fracture
|
N/A | |
Recruiting |
NCT05668182 -
A Case Series: TRUMATCH Graft Cage for Segmental Long Bone Defects
|
||
Recruiting |
NCT05680987 -
Retrograde Femoral Nail-Advanced Outcomes for Fixation of Distal Femur and Femoral Shaft Fractures
|
N/A | |
Not yet recruiting |
NCT04918680 -
Prospective Post-market Study Examining the Effectiveness of the EcoFit®
|